Immuno-C protein concentrate of bovine whey data

BIME (Salt Lake City) announced that preliminary analysis of Phase II findings in six HIV-positive, cryptosporidiosis-infected patients show safety and tolerability.

The concentrate was given in hospitals through a naso-gastric tube continually over two weeks in the open-label trial. Patients have requested to continue the therapy and are being monitored as outpatients, the company said. ...